Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales ...

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has experienced a 60% sales increase in India between April and May.

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...